Skip to main content

Table 2 Literature review of hypofractionated radiotherapy outcomes for the treatment of prostate cancer in the postoperative setting

From: Salvage hypofractionated accelerated versus standard radiotherapy for the treatment of biochemical recurrence after radical prostatectomy (SHARE): the protocol of a prospective, randomized, open-label, superiority, multi-institutional trial

Study (ref.)

Median follow-up, months

bPFS, %

Toxicity scoring system

Acute toxicity, %

Late toxicity, %

GU

GI

GU

GI

Tandberg [30]

38.6

78.4a (4 years)

CTCAE v4.0b/RTOGc

≥ G2: 22; G3: 1d

G2: 5; ≥ G3: 0

G2: 39; ≥ G3: 11

G2:10; G3: 1d

Kruser [33]

32.4

67 (4 years)

RTOG

G2: 6.4; G3: 1d

G2: 14; ≥ G3: 0

G2: 15; ≥ G3: 0

G2: 4; ≥ G3: 0

Lewis [31]

48

75 (4 years)

CTCAE v4.0b/RTOGc

G2: 4; ≥ G3: 0

G2: 4; ≥ G3: 0

G2: 39; G3: 28

≥ G3: 2d

Cuccia [32]

30

73 (3 years)

CTCAE v4.0

G2: 4; ≥ G3: 0

G2: 18; ≥ G3: 0

G2: 2.6; G3: 2.6

G2: 6.6; ≥ G3: 0

Barra [34]

15.5

Not reported

CTCAE v4.0b/RTOGc

≥ G2: 0

≥ G2: 0

G2: 3.3; G3: 3.3

≥ G2: 0

Alongi [35]

22.8

Not reported

RTOG

G2: 10; ≥ G3: 0

G2: 20; ≥ G3: 0

G2: 8; G3: 3

≥ G2: 0

Saldi [27]

27

Not reported

CTCAE v4.0

G2: 8.9; ≥ G3: 0

G2: 9.8; ≥ G3: 0

Not reported

Not reported

Katayama [26]

Not reported

Not reported

CTCAE v4.0

≥ G2: 0

G2: 17.9; ≥ G3: 0

Not reported

Not reported

Gladwish [29]

24

Not reported

CTCAE v3.0b/RTOGc

G2: 3; G3: 3

≥ G2: 0

≥ G2: 1d

≥ G2: 2d

Macchia [28]

30

86.5 (5 years)

RTOG

G2: 17.7; G4: 1d

G2: 24.2; ≥ G3: 0

≥ G2: 7.3

≥ G2: 1.1

  1. bPFS biochemical progression-free survival, GU Genitourinary, GI gastrointestinal
  2. aPatients with a 12-month minimum follow-up were analyzed for bPFS
  3. bAcute
  4. cLate
  5. dNumber of patients